Last reviewed · How we verify
NCT07067021
Post-Cesarean Gastrointestinal Dysfunction
trial in Cesarean Section Surgery in 102 participants. Completed in 2 July 2025.
30 June 2025
Quick facts
| Lead sponsor | Elazıg Fethi Sekin Sehir Hastanesi |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 102 |
| Start date | 15 June 2025 |
| Primary completion | 30 June 2025 |
| Estimated completion | 2 July 2025 |
| Sites | 1 location across Turkey (Türkiye) |
Conditions studied
- Cesarean Section Surgery — all drugs for Cesarean Section Surgery →
- TAP Blocks — all drugs for TAP Blocks →
- Gastrointestinal Dysfunction — all drugs for Gastrointestinal Dysfunction →
Sponsor
Elazıg Fethi Sekin Sehir Hastanesi — full company profile →
Who can join
Adults 18 to 50, female only, with Cesarean Section Surgery or TAP Blocks. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
General anesthesia has a range of effects that can lead to gastrointestinal (GI) system dysfunctions in the postoperative period. These effects are linked to various factors, from the pharmacological properties of anesthetic agents to neurohumoral effects triggered by surgical stress. Commonly encountered GI dysfunctions include nausea and vomiting, abdominal distension due to decreased intestinal peristalsis and the postoperative inflammatory response, delayed gastric emptying, ileus, fatigue, and delayed initiation of oral feeding. These conditions can prolong hospital stay, increase treatment costs, and reduce patient comfort. In clinical practice, protecting GI function and preventing complications after general anesthesia are of great importance. One of the main goals of applying Enhanced Recovery After Surgery (ERAS) protocols is to reduce the surgical stress response, thereby promoting rapid recovery and improving GI functions. Postoperative gastrointestinal (GI) dysfunction after cesarean section is a common complication that negatively impacts the recovery process. This condition manifests with symptoms such as abdominal pain, nausea, vomiting, and an inability to pass flatus, and it can prolong hospital stay and increase costs. Opioid analgesics are known to negatively affect postoperative GI motility, and regional anesthesia techniques can alleviate these problems by reducing opioid requirements. Fascial plane blocks like the TAP block are thought to reduce somatic and visceral pain by injecting local anesthetics between the deep and superficial layers of the fascia, and may positively influence GI functions through sympathetic blockade. This study aims to observationally investigate the effect of ultrasound-guided transabdominal plane (TAP) block on postoperative gastrointestinal system (GI) dysfunctions in patients who have undergone cesarean section.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07067021
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cesarean Section Surgery
Currently open trials in the same condition.
- NCT07321041 — Effect of Delivery Time on Umbilical Cord Blood Gas Parameters in Cesarean Sections Under General and Spinal Anesthesia · recruiting
- NCT06704490 — Analysis of the Incidence and Risk Factors of Chronic Pain After Cesarean Section · recruiting
Other Elazıg Fethi Sekin Sehir Hastanesi trials
Trials by the same sponsor.
- NCT07435896 — Impact of Information and Participation on Decision Time for Tracheostomy or PEG in ICU Families · not yet recruiting
- NCT07480720 — Systemic Inflammation, Thyroid Autoimmunity and Neuroretinal Changes in Graves Disease · recruiting
- NCT07437443 — Burnout, Secondary Traumatic Stress and Inflammatory Biomarkers in ICU Healthcare Workers · not yet recruiting
- NCT07434362 — Serum Endocan, Alarin, and Galanin-Like Peptide Levels in Diabetic Retinopathy · NA · completed
- NCT07415928 — Inhibin B/FSH Ratio as a Predictor of Testicular Pathology in NOA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07067021 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Elazıg Fethi Sekin Sehir Hastanesi
- Last refreshed: 18 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07067021.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing